These results indicates that PRMT5 promotes cell cycle progression, and combination of PRMT5 inhibitors with cyclin‐dependent kinase (CDK) inhibitors may provide therapeutic value in pancreatic cancer. Here, PRMT5 is linked to pancreatic neoplasm.